Trial Profile
Non-interventional Study on Quality of Life, Efficacy and Tolerability of Nab-paclitaxel/Gemcitabine Firstline Therapy in Patients With Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms AIO-QoliXane/PARAGON; QoliXane; QoliXane/PARAGON
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 21 Sep 2020 Results of QOLIXANE portion of the study presented at the 45th European Society for Medical Oncology Congress
- 31 May 2020 Real life results of QOLIXANE portion of the study, presented at the 56th Annual Meeting of the American Society of Clinical Oncology